Table 1:
Baseline clinical and demographic characteristics
| Total Sample (n = 37) | |
|---|---|
| Demographic characteristics | |
| Female (No.) (%) | 21 (56.8) |
| Age at moyamoya diagnosis (median) (IQR, 25–75) (yr) | 10 (6.3–11.8) |
| Age at initial CVR (median) (IQR, 25–75) (yr) | 10.7 (7.5–14.7) |
| Time to follow-up (median) (IQR, 25–75) (mo) | 20.8 (13.7–84.1) |
| Moyamoya classification | |
| Idiopathic | 14 (37.8) |
| Syndromic | 23 (62.2) |
| NF1 | 9 (24.3) |
| Trisomy 21/other chromosomal disorders | 7 (18.9) |
| Sickle cell disease | 5 (13.5) |
| Postradiation vasculopathy | 2 (5.4) |
| Clinical presentation | |
| Stroke (No.) (%) | 12 (32.4) |
| Bilateral | 2 (5.4) |
| Right | 6 (16.2) |
| Left | 4 (10.8) |
| TIA (No.) (%) | 8 (21.6) |
| Seizure (No.) (%) | 3 (8) |
| Headaches (No.) (%) | 8 (21.6) |
| Asymptomatic (No.) (%) | 6 (16.2) |
| Other (No.) (%) | 2 (5.4) |
| Radiographic findings (No.) (%) | |
| Parenchymal | |
| Not ischemic | 8 (21.6) |
| Watershed | 12 (32.4) |
| Deep white matter | 1 (2.7) |
| Cortical | 12 (32.4) |
| Cortical | 3 (8.1) |
| Cortical ischemic and watershed | 14 (37.8) |
| Vascular | |
| Moyamoya laterality (No.) (%) | |
| Left | 8 (21.6) |
| Right | 6 (16.2) |
| Bilateral | 23 (62.2) |
| Grade of stenosis (No.) (%) | |
| 50%–74% Occlusion | 5 (13.5) |
| ≥75% Occlusion | 32 (86.5) |
Note:—NF1 indicates neurofibromatosis type 1.